{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T19:50:59Z","timestamp":1694375459461},"reference-count":21,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["lrjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.leukres.2014.01.010","type":"journal-article","created":{"date-parts":[[2014,2,3]],"date-time":"2014-02-03T01:47:53Z","timestamp":1391392073000},"page":"662-665","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Interferon decreases VEGF levels in patients with chronic myeloid leukemia treated with imatinib"],"prefix":"10.1016","volume":"38","author":[{"given":"L.","family":"Legros","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Guilhot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Huault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.X.","family":"Mahon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Preudhomme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Guilhot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.O.","family":"Hueber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2014.01.010_bib0005","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2014.01.010_bib0010","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.drup.2009.06.001","article-title":"Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches","volume":"12","author":"Konopleva","year":"2009","journal-title":"Drug Resist Update"},{"key":"10.1016\/j.leukres.2014.01.010_bib0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/sonc.2002.37264","article-title":"Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications","volume":"29","author":"Ferrara","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.leukres.2014.01.010_bib0020","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/ijc.22180","article-title":"Microvascular endothelial cells increase proliferation and inhibit apoptosis of native human acute myelogenous leukemia blasts","volume":"119","author":"Hatfield","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.leukres.2014.01.010_bib0025","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1182\/blood.V96.6.2240","article-title":"Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes","volume":"96","author":"Aguayo","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.01.010_bib0030","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1172\/JCI8978","article-title":"Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration","volume":"106","author":"Dias","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.leukres.2014.01.010_bib0035","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/sj.leu.2402769","article-title":"Clinicopathologic correlations of bone marrow angiogenesis in chronic myeloid leukemia: a morphometric study","volume":"17","author":"Korkolopoulou","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2014.01.010_bib0040","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1182\/blood-2003-08-2695","article-title":"Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia","volume":"104","author":"Legros","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.01.010_bib0045","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2014.01.010_bib0050","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2014.01.010_bib0055","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood.V89.6.1870","article-title":"Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia","volume":"89","author":"Fiedler","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.01.010_bib0060","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1182\/blood.V97.5.1427","article-title":"Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes","volume":"97","author":"Bellamy","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.01.010_bib0065","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1182\/blood.V99.6.2265","article-title":"Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia","volume":"99","author":"Verstovsek","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.01.010_bib0070","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.leukres.2010.04.010","article-title":"Pegylated IFN-alpha2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone","volume":"35","author":"Nicolini","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2014.01.010_bib0110","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Clark RE assessment of BCR\u2013ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2014.01.010_bib0115","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/ajh.23238","article-title":"Early landmark analysis of imatinib treatment in CML chronic phase: less than 10% BCR\u2013ABL by FISH at 3 months associated with improved long-term clinical outcome. Am J Hematol","volume":"87","author":"Ohm","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2014.01.010_bib0085","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/jnci\/95.6.437","article-title":"Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis","volume":"95","author":"von Marschall","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.leukres.2014.01.010_bib0090","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","article-title":"Combination of pegylated IFN-alpha2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia","volume":"118","author":"Simonsson","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.01.010_bib0095","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/leu.2012.313","article-title":"Re-emergence of interferon-alpha in the treatment of chronic myeloid leukemia","volume":"27","author":"Talpaz","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2014.01.010_bib0100","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nrm3272","article-title":"A family business: stem cell progeny join the niche to regulate homeostasis","volume":"13","author":"Hsu","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.leukres.2014.01.010_bib0105","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrm3184","article-title":"Dynamic niches in the origination and differentiation of haematopoietic stem cells","volume":"12","author":"Wang","year":"2011","journal-title":"Nat Rev Mol Cell Biol"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212614000289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212614000289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T00:31:50Z","timestamp":1597451510000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212614000289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0145212614000289"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2014.01.010","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interferon decreases VEGF levels in patients with chronic myeloid leukemia treated with imatinib","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2014.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}